Paper 10 - THE NOVEL KIT INHIBITOR IDRX-42 SHOWS PROMISING ACTIVITY IN 2ND AND LATER-LINE GASTROINTESTINAL STROMAL TUMORS: RESULTS FROM A PHASE 1 STUDY (STRATEGIST 1)

Author(s)

• 

  Suzanne George, MD (she/her/hers)

  Chief of Sarcoma Center
  Dana-Farber Cancer Institute
  Boston, Massachusetts, United States

  Slides

Co-Author(s)

• 

  Michael C. Heinrich, MD

  Professor of Medicine
  Portland VA Health Care System and OHSU Knight Cancer Institute
  Portland, Oregon, United States
• JT

  Jonathan Trent, MD, PhD

  Sylvester Comprehensive Cancer Center, University of Miami Health System
  Miami, Florida, United States
• CS

  César Serrano, MD, PhD

  Vall d’Hebron Institute of Oncology
  Barcelona, Catalonia, Spain
• SB

  Sebastian Bauer, MD (he/him/his)

  Director
  Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, and German Cancer Consortium (DKTK), Partner Site University Hospital Essen
  Essen, Nordrhein-Westfalen, Germany
• Mv

  Margaret von Mehren, MD

  Fox Chase Cancer Center
  Philadelphia, Pennsylvania, United States
• 

  Neeta Somaiah, MD

  Professor & Deputy ChairSarcoma Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• PR

  Peter Reichardt, MD, PhD

  Helios Klinikum Berlin-Buch
  Berlin, Berlin, Germany
• GD

  George Demetri, MD

  Dana-Farber Cancer Institute – Sarcoma Center; IDRx
  Boston, Massachusetts, United States
• NL

  Nick Lydon, PhD

  IDRx
  Plymouth, Massachusetts, United States
• DK

  David Kerstein, MD

  IDRx
  Plymouth, Massachusetts, United States
• JV

  Jaap Verweij, MD, PhD

  IDRx
  Plymouth, Massachusetts, United States
• VK

  Vivek Kadambi, PhD

  IDRx
  Plymouth, Massachusetts, United States
• JC

  Jessica Christo, n/a

  IDRx
  Plymouth, Massachusetts, United States
• SK

  Sean Kim, PhD

  IDRx
  Plymouth, Massachusetts, United States
• DJ

  Debbie Johnson, BS

  IDRx
  Plymouth, Massachusetts, United States
• JS

  James Shao, MS

  IDRx
  Plymouth, Massachusetts, United States
• 

  Patrick Schöffski, Prof Dr

  Head of Department General Medical Oncology
  Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven
  Leuven, Vlaams-Brabant, Belgium